Paul G. Richardson, MD, discusses the response rates observed in the first-in-human phase 1 trial of CC-92480 and dexamethasone in patients with relapsed/refractory multiple myeloma.
Paul G. Richardson, MD, clinical program leader and director of Clinical Research for the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute, and RJ Corman Professor of Medicine at Harvard Medical School, discusses the response rates observed in the first-in-human phase 1 trial (NCT03374085) of CC-92480 and dexamethasone in patients with relapsed/refractory multiple myeloma.
Richardson said the overall response rate (ORR) for all of the evaluable patients in the study was about 21%, and the ORR for the patients treated at the maximum tolerated dose was encouraging at 40%, including 2 patients with complete response. When Richardson and the investigators looked at the best schedule, the response rate was at about 55% for the recommended phase 2 dose.
The majority of patients, about 70%, who were receiving the combination at 1 mg for 3 weeks and then were off for 1 week, were triple-class refractory and achieved complete responses and very good partial responses, which was exciting, according to Richardson.
For patients who had extramedullary disease and were receiving 1 mg, there were observed responses reflected by paraproteins and the disappearance of extramedullary disease on scans, which was something the investigators did not expect, Richardson says. All of the responses were durable in the study.